328 related articles for article (PubMed ID: 35212025)
1. Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study.
Viudez-Martínez A; Pascual-Carrasco A; Beltrán-Blasco I; Hernandez-Lorido R; F Ruiz de Apodaca R
J Clin Pharm Ther; 2022 Jun; 47(6):814-823. PubMed ID: 35212025
[TBL] [Abstract][Full Text] [Related]
2. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
[TBL] [Abstract][Full Text] [Related]
3. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
4. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
[TBL] [Abstract][Full Text] [Related]
5. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U
J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727
[TBL] [Abstract][Full Text] [Related]
6. Galcanezumab effect on "whole pain burden" and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience.
Silvestro M; Tessitore A; Orologio I; De Micco R; Tartaglione L; Trojsi F; Tedeschi G; Russo A
J Headache Pain; 2022 Jun; 23(1):69. PubMed ID: 35698070
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
[TBL] [Abstract][Full Text] [Related]
8. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine.
Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ
Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850
[TBL] [Abstract][Full Text] [Related]
9. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience.
Russo A; Silvestro M; Scotto di Clemente F; Trojsi F; Bisecco A; Bonavita S; Tessitore A; Tedeschi G
J Headache Pain; 2020 Jun; 21(1):69. PubMed ID: 32517693
[TBL] [Abstract][Full Text] [Related]
10. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
Curone M; Tullo V; Didier HA; Bussone G
Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
12. Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.
Alex A; Vaughn C; Rayhill M
Headache; 2020 Nov; 60(10):2454-2462. PubMed ID: 32969035
[TBL] [Abstract][Full Text] [Related]
13. Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada.
Eghtesadi M; Leroux E; Pagé G
Clin Drug Investig; 2021 Aug; 41(8):733-739. PubMed ID: 34287786
[TBL] [Abstract][Full Text] [Related]
14. Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study).
Vernieri F; Altamura C; Brunelli N; Costa CM; Aurilia C; Egeo G; Fofi L; Favoni V; Pierangeli G; Lovati C; Aguggia M; d'Onofrio F; Doretti A; Di Fiore P; Finocchi C; Rao R; Bono F; Ranieri A; Albanese M; Cevoli S; Barbanti P;
J Headache Pain; 2021 May; 22(1):35. PubMed ID: 33941080
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
[No Abstract] [Full Text] [Related]
16. A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.
Camporeale A; Kudrow D; Sides R; Wang S; Van Dycke A; Selzler KJ; Stauffer VL
BMC Neurol; 2018 Nov; 18(1):188. PubMed ID: 30413151
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of erenumab in chronic migraine: A Croatian real-world experience.
Mahović D; Bračić M; Jakuš L; Vukovic Cvetkovic V; Krpan M
Clin Neurol Neurosurg; 2022 Mar; 214():107169. PubMed ID: 35151970
[TBL] [Abstract][Full Text] [Related]
18. Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients.
Kwon S; Gil YE; Lee MJ
Cephalalgia; 2022 Jul; 42(8):705-714. PubMed ID: 35301884
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial.
Stauffer VL; Dodick DW; Zhang Q; Carter JN; Ailani J; Conley RR
JAMA Neurol; 2018 Sep; 75(9):1080-1088. PubMed ID: 29813147
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study.
Jakate A; Blumenfeld AM; Boinpally R; Butler M; Borbridge L; Contreras-De Lama J; McGeeney D; Periclou A; Lipton RB
Headache; 2021 Apr; 61(4):642-652. PubMed ID: 33818780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
